Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Zastaprazan (JP-1366) in Healthy Volunteers
NCT05814809Phase 1Completed
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Sep 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zastaprazan in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) (2 arms), sponsored by Onconic Therapeutics Inc. Primary endpoints: Area Under the Concentration-time Curve from time 0 to the last measurable concentration at 34 hours and Maximum Plasma Concentration at 34 hours. Started Sep 2022; status: completed.
02
Drugs
zastaprazan
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05814809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814809.